Literature DB >> 27002463

Attitudes Toward Use of Benzodiazepines among U.S. Hospice Clinicians: Survey and Review of the Literature.

Andrew Kamell1, Lauren Kelley Smith2.   

Abstract

BACKGROUND: Benzodiazepines are commonly used in inpatient hospices internationally. U.S. hospice clinician views toward benzodiazepines are unknown.
OBJECTIVES: Study objectives were (1) to assess inpatient hospice clinician attitudes towards the benefits of benzodiazepines for various indications and (2) to compare these attitudes to current clinical recommendations and literature.
METHODS: A survey was developed and distributed to hospices with inpatient units nationwide. Results were analyzed, then compared to current clinical guidelines. Literature review was performed. U.S. hospice physicians and nurses were the study subjects. Participants were asked to indicate their level of agreement regarding benefit from benzodiazepines for various end-of-life symptoms and to answer questions regarding benzodiazepines in delirium.
RESULTS: Of 143 surveys returned, 128 surveys were completed. For anxiety, 80% of participants agreed that benzodiazepines were beneficial for restlessness, dyspnea 77%, insomnia 68%, dying process 65%, agitation 57%, nausea 54%, hyperactive delirium 42%, and severe pain 38%. Nurses found benzodiazepines beneficial for more indications than physicians. Over 50% reported benzodiazepines on their order sets for agitation, insomnia, acute anxiety, chronic anxiety, chronic panic, restlessness, seizures, and withdrawal. Among physicians, 39% believe that benzodiazepines are overused within their own hospice. A literature review found very limited evidence of overall benefit from benzodiazepines for the symptoms listed above. In addition, this revealed significant evidence for risks and harms from benzodiazepines, particularly in patients at risk for delirium.
CONCLUSIONS: Benzodiazepines are viewed favorably by most hospice nurses and many hospice physicians for various indications, despite little supportive clinical evidence along with significant potential for harm.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27002463      PMCID: PMC4860624          DOI: 10.1089/jpm.2015.0376

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  42 in total

1.  Features of subsyndromal and persistent delirium.

Authors:  David Meagher; Dimitrios Adamis; Paula Trzepacz; Maeve Leonard
Journal:  Br J Psychiatry       Date:  2011-11-10       Impact factor: 9.319

Review 2.  The management of dyspnea in cancer patients: a systematic review.

Authors:  Raymond Viola; Cathy Kiteley; Nancy S Lloyd; Jean A Mackay; Julie Wilson; Rebecca K S Wong
Journal:  Support Care Cancer       Date:  2008-01-24       Impact factor: 3.603

Review 3.  Review article: terminal delirium in geriatric patients with cancer at end of life.

Authors:  Deborah D Moyer
Journal:  Am J Hosp Palliat Care       Date:  2010-11-07       Impact factor: 2.500

4.  Benzodiazepine and sedative-hypnotic use among older seriously Ill veterans: choosing wisely?

Authors:  Melissa M Garrido; Holly G Prigerson; Joan D Penrod; Shatice C Jones; Kenneth S Boockvar
Journal:  Clin Ther       Date:  2014-11-04       Impact factor: 3.393

Review 5.  Anticipatory nausea and vomiting due to chemotherapy.

Authors:  Charles Kamen; Mohamedtaki A Tejani; Kavita Chandwani; Michelle Janelsins; Anita R Peoples; Joseph A Roscoe; Gary R Morrow
Journal:  Eur J Pharmacol       Date:  2013-10-21       Impact factor: 4.432

Review 6.  Management of common symptoms in terminally ill patients: Part II. Constipation, delirium and dyspnea.

Authors:  D D Ross; C S Alexander
Journal:  Am Fam Physician       Date:  2001-09-15       Impact factor: 3.292

7.  Prevalence and risk factors for development of delirium in surgical and trauma intensive care unit patients.

Authors:  Pratik Pandharipande; Bryan A Cotton; Ayumi Shintani; Jennifer Thompson; Brenda Truman Pun; John A Morris; Robert Dittus; E Wesley Ely
Journal:  J Trauma       Date:  2008-07

8.  Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial.

Authors:  Pratik P Pandharipande; Brenda T Pun; Daniel L Herr; Mervyn Maze; Timothy D Girard; Russell R Miller; Ayumi K Shintani; Jennifer L Thompson; James C Jackson; Stephen A Deppen; Renee A Stiles; Robert S Dittus; Gordon R Bernard; E Wesley Ely
Journal:  JAMA       Date:  2007-12-12       Impact factor: 56.272

9.  A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients.

Authors:  W Breitbart; R Marotta; M M Platt; H Weisman; M Derevenco; C Grau; K Corbera; S Raymond; S Lund; P Jacobson
Journal:  Am J Psychiatry       Date:  1996-02       Impact factor: 18.112

Review 10.  Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit.

Authors:  Juliana Barr; Gilles L Fraser; Kathleen Puntillo; E Wesley Ely; Céline Gélinas; Joseph F Dasta; Judy E Davidson; John W Devlin; John P Kress; Aaron M Joffe; Douglas B Coursin; Daniel L Herr; Avery Tung; Bryce R H Robinson; Dorrie K Fontaine; Michael A Ramsay; Richard R Riker; Curtis N Sessler; Brenda Pun; Yoanna Skrobik; Roman Jaeschke
Journal:  Crit Care Med       Date:  2013-01       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.